Toggle navigation
About
Abstract
Editorial Board
Publication Schedule
Subscription & Newsletter
Contact
Issues
This issue
14-3
All issues
Download PDF
Download EPUB
Editor's Selection
This issue
14-3
Browse by topic
Browse by contributor
Dialogue & Opinion
Abstracts
Abstracts
Search
Classification List
Abstracted Journals
Index of Authors
News & Reports
Home
Issue 14-3
News Flashes
advertisement
News Flashes
IGR 14-3
Does axonal cytoskeletal disruption precede axon thinning?
Caffeine consumption and exfoliation
Determining a person's legal fitness to drive
Translaminar pressure gradient in sustained zero gravity
Glaucoma and reading
Phacoemulsification is a viable treatment option for IOP reduction in CACG not controlled by medication and laser iridotomy
Phaco- vs. trabeculectomy in chronic angle-closure glaucoma
Retinal nerve fiber layer defect in highly myopic eyes with glaucoma
Profibrotic activities of TGF-β2 mediated by the induction of the connective tissue growth factor
The costliest 5% of newly-diagnosed OAG patients were responsible for 24% of all glaucoma related charges
Retinal ganglion cell loss is accompanied by antibody depositions and increased levels of microglia after immunization with retinal antigens
Subspecialization in glaucoma surgery
It remains to be proven if 'higher surgeon volume' is associated with 'better results in peri-operative and long-term outcomes
Much to learn about MIGS
Issue
14-3
Table of Contents
Editor's Selection
Change Issue
26-1
25-4
25-3
25-2
25-1
24-4
24-3
24-1/2
23-4
23-3
23-2
23-1
22-4
22-3
22-2
22-1
21-4
21-3
21-2
21-1
20-4
20-3
20-2
20-1
19-4
19-3
19-2
19-1
18-4
18-3
18-2
18-1
17-4
17-3
17-2
17-1
16-4
16-3
16-2
16-1
15-4
15-3
15-2
15-1
14-4
14-3
14-2
14-1
13-4
13-3
13-2
13-1
12-4
12-3
12-2
12-1
11-4
11-3
11-2
11-1
10-4
10-3
10-2
10-1
9-4
9-3
9-2
9-1
8-4
8-3
8-2
8-1
7-3
7-2
7-1
6-3
6-2
6-1
5-3
5-2
5-1
4-3
4-2
4-1
3-3
3-2
3-1
2-3
2-2
2-1
1-3
1-2
1-1
advertisement
We would like to use Google Analytics to see which parts of the review are read. It is only used to count visits, never for advertising.
Privacy statement
Decline
Accept
